Who
Daniel Donovan
Director
Company insider
Files Form 4 as: Director, Intensity Therapeutics; Director, Panbela Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 27 Mar 2023
- Last trade
- 16 Jul 2026
- Last filed
- 20 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 20 Jul 2026 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 2 May 2025filed 6 May 2025 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 6 Mar 2024filed 7 Mar 2024 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 27 Mar 2023filed 29 Mar 2023 | Panbela Therapeuticsoption or derivative | SEC FORM 4 Code A | —8,333 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.